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Mutations in EOGT Confirm the Genetic Heterogeneity
of Autosomal-Recessive Adams-Oliver Syndrome
Ranad Shaheen,1 Mona Aglan,2 Kim Keppler-Noreuil,3 Eissa Faqeih,4 Shinu Ansari,1 Kim Horton,5
Adel Ashour,2 Maha S. Zaki,2 Fatema Al-Zahrani,1 Anna M. Cueto-Gonza´lez,6 Ghada Abdel-Salam,2
Samia Temtamy,2 and Fowzan S. Alkuraya1,7,*
Adams-Oliver syndrome (AOS) is a rare, autosomal-dominant or -recessive disorder characterized primarily by aplasia cutis congenita
and terminal transverse limb defects. Recently, we demonstrated that homozygous mutations in DOCK6 cause an autosomal-recessive
form of AOS. In this study, we sought to determine the contribution of DOCK6mutations to the etiology of AOS in several consanguin-
eous families. In two of the five families studied, we identified two homozygous truncatingmutations (a splice-sitemutation and a frame-
shift duplication).DOCK6 sequencing revealed nomutation in the remaining three families, consistent with their autozygositymapping
and linkage-analysis results, which revealed a single candidate locus in 3p14.1 on three different haplotype backgrounds in the three
families. Indeed, exome sequencing in one family revealed one missense mutation in EOGT (C3orf64), and subsequent targeted
sequencing of this gene revealed a homozygous missense mutation and a homozygous frameshift deletion mutation in the other
two families. EOGT encodes EGF-domain-specific O-linked N-acetylglucosamine (O-GlcNAc) transferase, which is involved in the
O-GlcNAcylation (attachment of O-GlcNAc to serine and threonine residues) of a subset of extracellular EGF-domain-containing
proteins. It has a documented role in epithelial-cell-matrix interactions in Drosophila, in which deficiency of its ortholog causes wing
blistering. Our findings highlight a developmental role of O-GlcNAcylation in humans and expand the genetic heterogeneity of auto-
somal-recessive AOS.Adams-Oliver syndrome (AOS [MIM 100300]) is a rare
congenital disorder characterized by aplasia cutis conge-
nita (ACC) and terminal transverse limb defects (TTLDs).
Additional abnormalities in other organs (e.g., the heart,
brain, and eye) might also be present with variable
expressivity.1–3 Although AOS was originally described as
an autosomal-dominant entity, subsequent reports on
consanguineous families have suggested that autosomal-
recessive inheritance is also possible.4,5 Indeed, the recent
revelation that dominant mutations in ARHGAP31 (MIM
610911) and recessive mutations in DOCK6 (MIM
614194), both of which encode proteins involved in the
regulation of two important actin cytoskeleton regulators,
RAC1 and CDC42, confirms that notion.6,7 The heteroge-
neity of autosomal-dominant AOS was demonstrated by
the recent identification of dominant mutations in RBPJ
(MIM 147183), encoding the primary transcriptional regu-
lator for NOTCH signaling, in some AOS individuals.8 It
remains unclear how RAC1- and CDC42-mediated cyto-
skeletal dysregulation and perturbed NOTCH signaling
converge on the pathogenesis of AOS, which has histori-
cally been proposed to entail vascular disruption, given
that the latter can theoretically explain the major findings
of AOS. It also remains unknown whether recessive AOS is
genetically heterogeneous and, if it is, how the additional
locus (or loci) might add to our understanding of the path-
ogenesis of this developmental disorder. In view of the
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to conduct genetic analysis of a number of families with
one or more AOS-affected individuals to explore the
genetics of the recessive form of the disease.
Seven affected individuals from five families were
enrolled under a protocol approved by the institutional
review board at King Faisal Specialist Hospital and Research
Center (research advisory council 2080006) after signing
written informed consent. Blood samples were collected
from the affected individuals, their parents, and, when
available, their unaffected siblings. The five families are
consanguineous; Table 1 summarizes their clinical fea-
tures, and a few representative images are shown in Fig-
ure 1. Autozygome analysis was performed on all affected
individuals with the Axiom SNP platform (Affymetrix,
Santa Clara, CA, USA) and was followed by autoSNPa
genome-wide determination of runs of homozygosity
(ROHs) as surrogates of autozygosity as described before.9
The index individuals in families AOS_F1 (IV:4) and
AOS_F2 (IV:1) were each found to harbor an ROH that
overlaps with DOCK6. Subsequent direct sequencing re-
vealed that AOS_F1 IV:4 harbors a 1 bp duplication that
results in a frameshift and the introduction of a premature
stop codon (c.2520dupT [p.Arg841Serfs*6]; RefSeq acces-
sion number NM_020812.3) (Figure S1A, available online).
Similarly, sequencing of DOCK6 in AOS_F2 IV:1 revealed
a homozygous splice-acceptor-site mutation (c.4107-
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Table 1. Summary of Clinical Findings of AOS Individuals
Family
AOS_F1 AOS_F2 AOS_F3 AOS_F4 AOS_F5
IV:4 IV:1 IV:4 IV:2 V:1 IV:4 IV:5
Homozygous
mutation
DOCK6a c.2520dupT DOCK6a c.4107–1G>C EOGT c.620G>C EOGT c.1074delA EOGT c.1130G>A EOGT c.1130G>A EOGT c.1130G>A
Age 12 months 2 years 35 days 32 months 3 years 10 years 12 years
Gender male female female male female female male
Cutis aplasia occipital scalp and
abdomen
þ parietal scalp defect
11 3 15 cm in diameter
þ (5 cm scalp defect) a small bony defect (5 cm)
in the skull vault involves
both parietal bones and is
covered with hairless
scalp skin
a small midline bony
defect (1 cm) in the skull
vault is covered with
sparsely haired scalp skin
a large midline skull
defect (5 cm) involves
both parietal bones
and is covered with
hairless scalp skin
Terminal transverse
limb defects
tapering fingers and
hypoplastic distal
phalanges of the hands
and feet
þ (hypoplastic terminal
phalanges)
distal transverse defect,
dysplastic right big toe,
and hypoplastic nails in
the other right toes
bilateral hypoplasia in
third toes and toenails
(r > l)
left foot: absent distal
phalanges, absent middle
phalanges of third and
fourth toes, soft tissue
syndactyly, and
hypoplastic nails
left foot: absent terminal
phalanges of all toes.
symmetrical in both
feet; absent terminal
phalanges of all toes
and severe dysplastic
nails
right foot: absent nails of
first, second, third, and
fourth toes
dysplastic nails in all toes
right foot: hypoplastic
second and third
phalanges in second,
third, and fourth toes and
absent terminal phalanx
of fifth toe
Congenital heart
disease
aortic valve dysplasia ND ASD-II muscular VSD and PDA
(resolved)
no no no
Microphthalmia no hypoplastic disc no no no no no
Other depressed nasal bridge,
bulbous nasal tip, single
palmar creases, dilation
of cerebral ventricles,
and periventricular
calcifications
intracranial
periventricular
calcification, pachygyria
(especially posteriorly),
and uncontrolled
seizures
normal neuroimaging left temporal and occipital
lobe infarcts (presumed
prenatal origin), umbilical
hernia, and speech and
fine motor delays
cutis marmorata, six cafe´
au lait patches (less than
0.5 cm) on abdomen and
chest, and small umbilical
hernia
ND ND
sister with dilation of
cerebral ventricles,
periventricular
calcifications, aplasia cutis
congenita, gastroschisis,
convulsions, and distal
malformed fingers
and toes
The following abbreviations are used: ND, not determined; ASD-II, atrial septal defect type II; VSD, ventricular septal defect; and PDA, patent ductus arteriosus.
aRefSeq accession number NM_020812.3.
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Figure 1. Identification of Five Consanguineous AOS-Affected Families
The index individual is indicated with an arrow in each pedigree, and asterisks denote individuals whose DNAwas available for analysis.
Please note that the degree of consanguinity between III:1 and III:2 in AOS_F4 is uncertain.
(A–E) Representative clinical images of the index individuals from families AOS_F2, AOS_F3, and AOS_F5. Clinical photographs of
AOS_F2 IV:1 show the hypoplastic terminal phalanges (A and B) and periventricular calcifications, thick cortex, and posterior pachygyria
(C). Clinical photographs show the cutis aplasia in AOS_F3 IV:4 (D) and AOS_F5 V:1 (E).primers confirmed that the mutation replaces the con-
sensus acceptor site by a cryptic site in the downstream
exon (exon 33), leads to the loss of 7 bp from exon 33,
and thus results in a frameshift and the introduction of a
premature stop codon (p.Thr1370Metfs*19) (Figures S1B
and S1C).
None of the affected individuals in the remaining three
families—AOS_F3 (IV:4), AOS_F4 (IV:2), and AOS_F5
(V:1, IV:4, and IV:5)—had an ROH overlapping with
DOCK6, and, consistent with that finding, sequencing of
this gene revealed no mutation. On the other hand, the
autozygome of these individuals overlapped on a previ-600 The American Journal of Human Genetics 92, 598–604, April 4, 2ously unreported 2,744,933 bp locus corresponding
to the genomic region chr3: 66,612,406–69,357,338
(GRCh37/hg19) (Figure 2A). This locus was confirmed by
linkage analysis, which revealed a single peak (LOD of
~3.7) corresponding to the same critical ROH highlighted
by autozygome analysis (Figure 2B). Exome sequencing
of AOS_F3 IV:4 and subsequent application of the filtration
scheme that we described previously (after filtering out all
variants listed in dbSNP, we considered only those that
were homozygous, coding or splicing, predicted to be path-
ogenic in silico, and absent in 230 Saudi exomes), revealed
five missense variants, two of which turned out to be013
Figure 2. Identification of an AOS-Associated Locus on Chromosome 3
(A) AutoSNPa output for chromosome 3 reveals an ROH (boxed in red) exclusively shared among AOS_F3 IV:4, AOS_F4 IV:2, and AOS_F5
V:1, IV:4, and IV:5.
(B) Combined genome-wide linkage analysis of the three families revealed a single maximal peak with a LOD score of ~3.7 on chromo-
some 3.
(C) Upper panel: diagram of EOGT (red color denotes coding exons, yellow denotes UTRs, and triangles denote mutation sites). Lower
panel: sequence chromatograms of the three mutations in EOGT (control tracing is shown for comparison) show the two missense
variants in AOS_F3 IV:4 and AOS_F5 V:1 (mutation sites are denoted by asterisks, and the 1 bp deletion in AOS_F4 IV:2 is denoted by
a red line). Please note that the NCBI contains only an alternatively spliced version (RefSeq NM_173654.1), according to which the
nomenclature of the three mutations will be as follows: c.620G>C (p.Trp207Ser) (unchanged), c.832–791delA (instead of c.1074delA
[p.Gly359Aspfs*28]), and c.878G>A (p.Arg293Gln) (instead of c.1130G>A [p.Arg377Gln]).sequencing artifacts. However, we prioritized the candi-
dacy of the missense variant (c.620G>C [p.Trp207Ser];
RefSeq NM_173654.1; ENST00000383701.3) in EOGT
(C3orf64) because it was the only one among the three
variants to fall within the critical locus. Indeed, Sanger
sequencing confirmed this homozygous mutation in
AOS_F3 IV:4, and her parents were found to be carriers
(Figure 2C). We then fully sequenced EOGT in AOS_F4
IV:2 and AOS_F5 members V:1, IV:4, and IV:5. We identi-
fied a 1 bp homozygous deletion creating a frameshift
and premature stop codon (c.1074delA [p.Gly359Aspfs*
28]) in AOS_F4 IV:2 and a homozygous missense mutation
(c.1130G>A [p.Arg377Gln]) in AOS_F5 individuals V:1,
IV:4, and IV:5. These variants were absent in 230 Saudi
exomes, the 1000 Genomes Project, and the National
Heart, Lung, and Blood Institute (NHLBI) Exome VariantThe AmServer. Furthermore, we fully sequenced EOGT in 100
normal Arabs (all affected individuals are Arabs) in an
attempt to address the possibility that this gene accumu-
lates pathogenic variants that are tolerated in normal indi-
viduals, but we identified no such variants. In addition, the
two missense variants affect two absolutely conserved resi-
dues down to C. elegans, and both SIFT and PolyPhen
predict them to be highly pathogenic (Figure S2). These
data strongly suggest that each of the three alleles in
EOGT is disease causing in their respective families in the
homozygous state.
The addition of O-linked N-acetylglucosamine (O-
GlcNAc) moieties is a posttranslational modification that
influences the stability of a number of proteins and
regulates their role in various cellular mechanisms,
including cytokinesis, protein trafficking, epigenetic anderican Journal of Human Genetics 92, 598–604, April 4, 2013 601
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Figure 3. Whole-Mount In Situ Hybridization of Eogt during Mouse Embryonic Development
(A) An E10.5 mouse embryo shows expression in the growing edge of the limb bud.
(B) An E11.5 mouse embryo shows expression in the apical ectodermal ridge of the limbs.
(C) An E12.5 embryo shows the digit-condensation expression of Eogt mRNA (triangles) in the limbs.
(C1 and C2) Close-up views of the expression in the digits of the hindlimbs (C1) and forelimbs (C2) of the same E12.5 embryo as in (C).
(D) Sense control is shown for comparison in an E12.5 embryo. Eogt probes correspond to the area spanning nucleotides 91–816 and
830–1,537 of the coding region (RefSeq NM_175313.4).transcriptional regulation, and intracellular signaling in
response to environmental stimuli, such as nutrition and
stress.10–13 This glycosylation reaction is catalyzed by the
enzyme O-linked N-acetylglucosamine transferase (OGT)
but is readily reversedbyanother enzyme,N-acetyl-b-gluco-
saminidase (OGA), inorder tomaintain thedynamicnature
of thismodification,which is key to its role in regulating the
above-mentioned cellular processes.14–16 In humans, the
attachment of O-GlcNAc to serine and threonine resi-
dues as a form of posttranslational protein modification
(O-GlcNAcylation)has been implicated in thepathogenesis
of diabetes, Alzheimer disease (MIM 104300), and cancer,
but no developmental role has been assigned to this post-
translational modification to date.17–20 OGT is the only
known enzyme to effect O-GlcNAcylation, and it targets in-
tracellular proteins.21 However, it has recently been shown
that another enzyme, named EOGT (ER resident O-GlcNAc
transferase), is capable of O-GlcNAcylating secreted extra-
cellular proteins in Drosophila and mammals.22,23
In Drosophila, the O-GlcNAcylation of the extracellular
EGF domains of two membrane proteins (Dumpy and
Notch) was demonstrated.22,24,25 Remarkably, loss of Eogt
in developing wing discs of Drosophila caused wing blis-
tering, a well-documented phenotypic readout of the
dysregulation of cell-cell adhesion and cell-matrix interac-602 The American Journal of Human Genetics 92, 598–604, April 4, 2tion.22,26 Although loss of Eogtwas associated with demon-
strable loss of O-GlcNAcylation of Notch, the activity of
Notch was unaltered, and it was concluded that the
observed defect in the interaction of epithelial cells with
the apical extracellular matrix was mediated by Dumpy
instead.22 More recently, the same target motif (a Thr
residue located between the fifth and sixth conserved
cysteines of the folded EGF-like domains, or the
CXXGXS/TGXXC motif) in Drosophila Notch and Dumpy
was shown to be modified by O-GlcNAcylation in murine
NOTCH1 in a reaction catalyzed by the murine ortholog
EOGT.23 Furthermore, wing blistering in Eogt-knockout
Drosophilawas rescued by themurine ortholog, confirming
the conserved functional and developmental role of this
enzyme between Drosophila and mammals.23 In addition,
Eogt has been found to be expressed in the presomitic
mesoderm and a number of adult mouse tissues (including
the heart, lung, liver, spleen, and skeletal muscles) derived
from the mesoderm.23,27
In order to determine the developmental expression
pattern of Eogt, we performed whole-mount in situ hybrid-
ization on mouse embryos of various stages of develop-
ment. Expression of Eogt at embryonic day (E) 10.5 was
observed in the growing edge of the limb buds (Figure 3A).
At E11.5, EogtmRNAwas enriched in the apical ectodermal013
ridge of the limbs (Figure 3B). By E12.5, the expression of
Eogt assumed a digit-condensation pattern in the four
limbs (Figures 3C–3C2). Lack of comparable staining
with the corresponding sense probes confirmed specificity
of the observed signals (see Figure 3D for a representative
example).
The above data suggest that EOGT deficiency in humans
causes AOS through its effect on cell-cell or cell-matrix
interaction, processes that are known to be perturbed by
the actin cytoskeletal defects observed in individuals
with ARHGAP31 and DOCK6 mutations, thus providing
tantalizing evidence of a potential mechanistic overlap
that explains the phenotypic overlap. Another potential
overlap between EOGT-related AOS and that caused by
RBPJ mutations is that RBPJ is assumed (but not proven)
to modulate NOTCH signaling and that EOGT is known
to glycosylate NOTCH1 in mammals. The observation of
intact Notch signaling in the fruit fly that lacks Eogtmight
not necessarily hold true in mammals. Unfortunately, we
have no cells from any of the individuals with EOGTmuta-
tions to experimentally test their cytoskeleton and their
NOTCH signaling activity. Of note, very recent data
suggest that the motif recognized by EOGT is shared
among a large number of human proteins, many of which
reside in the extracellular matrix, so it is possible that the
pathogenesis of EOGT-related AOS might involve one or
more of these substrate proteins.28
In conclusion, we present evidence of genetic heteroge-
neity of autosomal-recessive AOS and implicate EOGT-
mutation-causingdefects inextracellular-proteinO-GlcNAc
modification in its pathogenesis. Our finding of an
individual with gastroschisis and molecularly con-
firmed AOS calls for future investigation of the role of
abnormal vascular development in the pathogenesis of
this disease in light of the expanding repertoire ofmolecular
targets.Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.cell.com/AJHG.Acknowledgments
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